NCT06995677View on ClinicalTrials.gov

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

September 30, 2028

Conditions
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationFGFR3 Gene Fusions
Interventions
DRUG

TYRA-300 60mg

Self-administered 60mg dose Oral tablet(s) given daily

DRUG

TYRA-300 50mg

Self-administered 50mg dose Oral tablet(s) given daily

DRUG

TYRA-300 Dose TBD

To Be Determined Dose: Self-administered Oral tablet(s) given daily

Trial Locations (3)

29572

RECRUITING

Carolina Urologic Research Center, Myrtle Beach

37209

RECRUITING

Urology Associates PC, Nashville

92123

RECRUITING

Genesis Research, San Diego

All Listed Sponsors
lead

Tyra Biosciences, Inc

INDUSTRY